IQ doesn't test everything related to intelligence. It surely recognizes forms of intelligence. More important is the person's talent in understanding science and biology. Also, there's no IQ requirement needed (as far as I know) in order to have a PhD. Do you think this should not be the case?
In this research they targeted isolated human cells, but in another study ( I think by Bezos / Altos Labs) older mice were targeted and over time, their skin began to look more and more youthful. No side effects were found there as well.
Nah. A "normal" brain is well balanced. We don't understand much about the brain but through observation it is noticeable that a brain specialized in one form of intelligence may affect other forms of intelligence. It is all about balancing processing power. That is why it is common that geniuses have some form of social quirk or difficulties with empathy.
Can You provide a link to this research?
www.sciencealert.com
“We welcome Paul as an important addition to our board of directors,” said Matt Posard, Stemson’s executive chairman of the board. “With more than 35 years of experience founding and leading therapeutics development companies from preclinical to clinical stage development and from start-up through IPO, Paul will provide valuable guidance to accelerate Stemson’s progress.”
Interesting!Paul Laikind, PhD, Joins Stemson Therapeutics Board of Directors
Stemson Therapeutics Corp., a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, awww.businesswire.com
Paul Laikind, PhD, Joins Stemson Therapeutics Board of Directors
Seasoned biotech entrepreneur and CEO will support Stemson’s efforts to develop the first iPSC-derived cell therapy to treat hair loss
April 18, 2022 12:00 PM Eastern Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Stemson TherapeuticsCorp., a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Paul Laikind, serial entrepreneur and former CEO of cell therapy company ViaCyte, has joined the Stemson Board of Directors. Paul brings significant company building and therapeutics development experience to the Stemson Board.
“We welcome Paul as an important addition to our board of directors,” said Matt Posard, Stemson’s executive chairman of the board. “With more than 35 years of experience founding and leading therapeutics development companies from preclinical to clinical stage development and from start-up through IPO, Paul will provide valuable guidance to accelerate Stemson’s progress.”
“I am delighted and honored to join Stemson’s Board of Directors,” said Paul. “Stemson’s unique combination of novel technologies to bioengineer hair follicles not only has the potential to help millions of people suffering from hair loss, but can more broadly advance the capabilities for cell therapy development across the industry. I look forward to working with the team and supporting their journey.”
Paul Laikind, PhD, was CEO of ViaCyte from 2012 until 2020, where he lead the development of the first stem cell-derived cell therapies designed to replace pancreatic beta cells for the treatment of Type 1 Diabetes. Paul led the company from the preclinical stage through the introduction of two product candidates into clinical trials before retiring at the end of 2020. A third product that Viacyte developed in collaboration with CRISPR Tx recently also entered clinical development.
Dr. Laikind served as Chief Business Officer and Senior Vice President of the Sanford Burnham Medical Research Institute from 2009 – 2011, focusing on enhancing the translational capabilities of the institute. From 1999 - 2009, Paul was cofounder and CEO of Metabasis Therapeutics, which concentrated on therapeutics development for metabolic and liver diseases. He took Metabasis from founding through IPO, and from preclinical to clinical stage development, with five products in the clinic. From 1986 – 1999, Paul cofounded and served as Vice President of Corporate Development at Gensia Pharmaceuticals where they developed small molecule therapies for the treatment of cardiovascular, neurological and inflammatory diseases. During that time, he cofounded and served as an advisor to Viagene from 1988 – 1994, the first commercially focused gene therapy company developing proprietary gene delivery technology to treat HIV, cancer and inherited disorders. Gensia, Viagene and Metabasis each completed successful initial public offerings and were eventually acquired for combined proceeds of over $3.5 billion.
Throughout his career, Dr. Laikind has played a leadership role in the evolving biotechnology industry. He serves or has served on the board of industry organizations including BIO, BIOCOM, CONNECT, and Alliance for Regenerative Medicine.
Paul earned his PhD in Biochemistry from the University of California, San Diego, and is a veteran of the US Navy.
“We are very lucky to have Paul join us. The next stage of Stemson’s development is to advance our first product toward human clinical trials,” stated Geoff Hamilton, cofounder and CEO of Stemson Therapeutics. “Paul’s tremendous business leadership experience and industry relationships, as well as his involvement developing similar technologies to Stemson’s while at ViaCyte, will help us guide the company toward that goal.
Assuming that things are looking up for Stemson regarding preclinical results, why are they then keeping it a secret from us? Wouldn't one think if the new preclinical results looked promising they would give a press release bragging that we did it, we've grown hairs on our mini pigs? All they report on now for news is we've hired new people to our board. I've tried reaching out to them a handful of times, even calling the top bigwigs, not one of them returned my calls. Not even the communications director is replying to me anymore. I've tried getting in touch with CEO Geoff Hamilton, Alexey Terskikh PhD, and Dr. Richard Chafoo. It is no doubt great they are hiring some of the best people in the biotech industry to develop their technology, who have successfully developed biotech solutions but until I hear from someone they are getting a degree of results from their mini pigs, I am not holding my breath that we're at the gates of the promised land. You know, what is so proprietary that they cannot just say to me yes, we've gotten somewhere with our experiments in pigs? If they would come forward with this information to me I'd have a lot more confidence in them. Maybe perhaps they are being overwhelmed with inquiries from interested people that they have no time to deal with people wanting information? I am very excited for this company and a fan no doubt but wish I could get a grip of what's really going on, surely we all here want to know this.
Hamilton doesn't give a sh*t on accidental guys like you or me, it's normal he doesn't answer calls, I don't know what you expected?
If he doesn't care about individuals, why should he care about finding a cure? It's not good. I yearn for a cure. He probably just does this because it provides him a living and could care less otherwise if a cure is found or not. It would be great if someone like Jeff Donovan was running the company instead of Geoff Hamilton, because Jeff Donovan is passionate about hair loss research, people and loves learning about the subject. It takes a special person to understand this problem or someone who has suffered or suffers from hair loss to address people who are desperate like myself and wanting answers. These companies need leaders, who care for those in need of answers and outreach. Cold corporate stiffs aren't the ideal types of people for this type of matter but are likely good for handling business, organization, raising money, functional management and making good hiring choices. They have their place in their areas of talent. At least that's how I see it. Giving a sh*t about people, even of the least concern to them should still be important for how a company is viewed by the public. If they don't give a sh*t about me, why should they give a sh*t about anyone or hair loss at all if it's just a job of trivial importance to their own personal priorities?
the truth is as you described, we mark sh*t as individuals for anyone
First of all, I don't know either, so take it with a grain of salt.
I've browsed this forum for years and had an account awhile ago, and it always amazes me how people think companies should just announce any and all progress they make. They don't owe us anything if they're not selling a product yet. All announcements like this do is cause people to go into a frenzy and harass them...and for startups, risks people trying to steal IP. Uber, DoorDash etc didn't go around announcing everything they were going to do - they developed, got funding in private, and moved forward. Stemson is already raising a lot of money so they don't need press for that at the moment.
I agree. Stemson can say whatever they want to say, whenever they want to say it. I'm cool with that. But one thing I'm confused about is why Stemson is trying to make entire follicles to implant them into bald scalps instead of just injecting cells into bald scalps.
Paul Laikind, PhD, Joins Stemson Therapeutics Board of Directors
Stemson Therapeutics Corp., a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, awww.businesswire.com
Paul Laikind, PhD, Joins Stemson Therapeutics Board of Directors
Seasoned biotech entrepreneur and CEO will support Stemson’s efforts to develop the first iPSC-derived cell therapy to treat hair loss
April 18, 2022 12:00 PM Eastern Daylight Time
SAN DIEGO--(BUSINESS WIRE)--Stemson TherapeuticsCorp., a private biotechnology company developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles, announced today that Paul Laikind, serial entrepreneur and former CEO of cell therapy company ViaCyte, has joined the Stemson Board of Directors. Paul brings significant company building and therapeutics development experience to the Stemson Board.
“We welcome Paul as an important addition to our board of directors,” said Matt Posard, Stemson’s executive chairman of the board. “With more than 35 years of experience founding and leading therapeutics development companies from preclinical to clinical stage development and from start-up through IPO, Paul will provide valuable guidance to accelerate Stemson’s progress.”
“I am delighted and honored to join Stemson’s Board of Directors,” said Paul. “Stemson’s unique combination of novel technologies to bioengineer hair follicles not only has the potential to help millions of people suffering from hair loss, but can more broadly advance the capabilities for cell therapy development across the industry. I look forward to working with the team and supporting their journey.”
Paul Laikind, PhD, was CEO of ViaCyte from 2012 until 2020, where he lead the development of the first stem cell-derived cell therapies designed to replace pancreatic beta cells for the treatment of Type 1 Diabetes. Paul led the company from the preclinical stage through the introduction of two product candidates into clinical trials before retiring at the end of 2020. A third product that Viacyte developed in collaboration with CRISPR Tx recently also entered clinical development.
Dr. Laikind served as Chief Business Officer and Senior Vice President of the Sanford Burnham Medical Research Institute from 2009 – 2011, focusing on enhancing the translational capabilities of the institute. From 1999 - 2009, Paul was cofounder and CEO of Metabasis Therapeutics, which concentrated on therapeutics development for metabolic and liver diseases. He took Metabasis from founding through IPO, and from preclinical to clinical stage development, with five products in the clinic. From 1986 – 1999, Paul cofounded and served as Vice President of Corporate Development at Gensia Pharmaceuticals where they developed small molecule therapies for the treatment of cardiovascular, neurological and inflammatory diseases. During that time, he cofounded and served as an advisor to Viagene from 1988 – 1994, the first commercially focused gene therapy company developing proprietary gene delivery technology to treat HIV, cancer and inherited disorders. Gensia, Viagene and Metabasis each completed successful initial public offerings and were eventually acquired for combined proceeds of over $3.5 billion.
Throughout his career, Dr. Laikind has played a leadership role in the evolving biotechnology industry. He serves or has served on the board of industry organizations including BIO, BIOCOM, CONNECT, and Alliance for Regenerative Medicine.
Paul earned his PhD in Biochemistry from the University of California, San Diego, and is a veteran of the US Navy.
“We are very lucky to have Paul join us. The next stage of Stemson’s development is to advance our first product toward human clinical trials,” stated Geoff Hamilton, cofounder and CEO of Stemson Therapeutics. “Paul’s tremendous business leadership experience and industry relationships, as well as his involvement developing similar technologies to Stemson’s while at ViaCyte, will help us guide the company toward that goal.
Turns out after speaking to my dad yesterday that he owns a lot of stock in Abbvie, one of the companies that is funding Stemson. If I make mention of this maybe I could get somewhere in the way of finding answers? I know Geoff will talk with important individuals but no doubt there is confidential information they don't want out there about things they're doing. Spencer Kobren (The Bald Truth) makes mention of it not to spill the beans about things Geoff told him in confidence.
Posters think they're clever & original when they attack the mental health of another poster BUT the sh!t happens in literally every thread sooner or later when one poster disagrees with another poster. It's the most unoriginal & dullard insult to be found at virtually every website where people are allowed to post. It's THE boring go-to default insult when someone can't think of a smart insult. It's also got bigotry built into it because the person using this kind of insult is insulting people with mental health problems and implying that people with psychological problems never have anything significant to add to a discussion and they should be ignored 100% of the time. And the person using the mental health insult is often gaslighting the poster he's insulting because the person he's insulting often has a valid point.
Bro you were literally calling people subhuman in the other thread. Spare us the novel.
